nach oben

Current Hypertension Reports

Erschienen in:

01.10.2013 | Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Hypertension after Kidney Transplantation: A Pathophysiologic Approach

verfasst von: Beje Thomas, David J. Taber, Titte R. Srinivas

Erschienen in: Current Hypertension Reports | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Post-transplant hypertension is associated with decreased graft and patient survival and cardiovascular morbidity. Unfortunately, post-transplant hypertension is often poorly controlled. Important risk factors include immunosuppressive medications, complications of the transplant surgery, delayed graft function, rejection, and donor and recipient risk factors. The effects of immunosuppressive medications are multifactorial including increased vascular and sympathetic tone and salt and fluid retention. The immunosuppressive agents most commonly associated with hypertension are glucocorticoids and calcineurin inhibitors. Drug therapy for hypertension should be based on the comorbidities and pathophysiology. Evidence-based approaches to defining and treating hypertension in renal transplant recipients are predominantly extrapolated from large-scale studies performed in the general population. Thus, there continues to be a need for larger studies examining the pathophysiology, diagnosis and treatment of hypertension in renal transplant recipients.

Djamali A, Samaniego M, Muth B, Muehrer R, Hofmann RM, Pirsch J, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol. 2006;1(4):623–40.PubMedCrossRef

Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant. 2004;4(10):1662–8.PubMedCrossRef

Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16(8):1545–9.PubMedCrossRef

El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527–35.PubMedCrossRef

• Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int. 2010;23(12):1191–204. Immunosuppression as a risk factor for cardiovascular disease and how to minimize this effect in the transplant patient.PubMedCrossRef

Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl 1):S117–31.PubMedCrossRef

Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet. 1985;2(8458):739–42.PubMedCrossRef

Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071–81.PubMedCrossRef

• Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis. 2011;57(2):331–41. Review of the HTN literature with a focus on the relationship of GFR with BP control and various immunosuppression strategies and the effect on BP.PubMedCrossRef

10.

Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest. 1994;93(5):2244–50.PubMedCrossRef

11.

Gardiner SM, March JE, Kemp PA, Fallgren B, Bennett T. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol. 2004;141(4):634–43.PubMedCrossRef

12.

• Chatzikyrkou C, Menne J, Gwinner W, Schmidt BM, Lehner F, Blume C, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29(12):2283–94. Extensive review on HTN in transplant with focus the effects of immunosuppression on HTN and the goals of therapy.PubMedCrossRef

13.

• Weir MR, Salzberg DJ. Management of hypertension in the transplant patient. J Am Soc Hypertens. 2011;5(5):425–32. The American Society of Hypertension position paper on HTN in the transplant patient.PubMedCrossRef

14.

Paoletti E, Gherzi M, Amidone M, Massarino F, Cannella G. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation. 2009;87(12):1864–9.PubMedCrossRef

15.

• Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation—evidence from the FAVORIT study. Clin Transplant. 2012;26(4):E438–46. The need for more adequate control of cardiac risk factors post-transplant, in particular HTN.PubMedCrossRef

16.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef

17.

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–S155.

18.

• Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. Am J Kidney Dis 2013 May 15. The presentation of published goals of therapy in post-transplant HTN.

19.

• Angeli F, Verdecchia P, Reboldi G. Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. Expert Rev Cardiovasc Ther. 2012;10(12):1467–70. That lowering BP below 120/80 might not be beneficial.PubMedCrossRef

20.

• ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85. That lowering BP below 120/80 might not be beneficial.PubMedCrossRef

21.

• Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep. 2012;14(6):556–66. J-curve phenomenon of DBP <80 mmHg associated with higher cardiac morbidity and mortality.PubMedCrossRef

22.

• Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep. 2012;14(1):89–96. Review of targets for BP in diabetic patients.PubMedCrossRef

23.

• Wadei HM, Textor SC. Hypertension in the kidney transplant recipient. Transplant Rev (Orlando). 2010;24(3):105–20. Review of HTN, mentions the importance of the relationship between goals of HTN therapy and time after transplant.CrossRef

24.

Stenehjem AE, Gudmundsdottir H, Os I. Office blood pressure measurements overestimate blood pressure control in renal transplant patients. Blood Press Monit. 2006;11(3):125–33.PubMedCrossRef

25.

Prasad GV, Nash MM, Zaltzman JS. A prospective study of the physician effect on blood pressure in renal-transplant recipients. Nephrol Dial Transplant. 2003;18(5):996–1000.PubMedCrossRef

26.

Haydar AA, Covic A, Jayawardene S, Agharazii M, Smith E, Gordon I, et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation. 2004;77(6):849–53.PubMedCrossRef

27.

• Fernandez Fresnedo G, Franco Esteve A, Gomez Huertas E, Cabello Chaves V, Diz Gomez JM, Osorio Moratalla JM, et al. Ambulatory blood pressure monitoring in kidney transplant patients: RETENAL study. Transplant Proc. 2012;44(9):2601–2. The importance of BP control and use of 24 ABPM in the follow-up of patients.PubMedCrossRef

28.

• Kayrak M, Gul EE, Kaya C, Solak Y, Turkmen K, Yazici R, et al. Masked hypertension in renal transplant recipients. Blood Press 2013 May 31. Importance of diagnosing masked HTN in the transplant patient and outcomes.

29.

• Beltran S, Crespo J, Kanter J, Alemany B, Gavela E, Avila A, et al. Ambulatory blood pressure monitoring in renal transplant patients: should it be routinely performed? Transplant Proc. 2010;42(8):2868–70. Utility of 24 ABPM in the renal transplant patient.PubMedCrossRef

30.

Wadei HM, Amer H, Taler SJ, Cosio FG, Griffin MD, Grande JP, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol. 2007;18(5):1607–15.PubMedCrossRef

31.

Hernandez D, Gonzalez A, Rufino M, Laynez I, de la Rosa A, Porrini E, et al. Time-dependent changes in cardiac growth after kidney transplantation: the impact of pre-dialysis ventricular mass. Nephrol Dial Transplant. 2007;22(9):2678–85.PubMedCrossRef

32.

Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation. 2001;72(1):107–11.PubMedCrossRef

33.

• Strozecki P, Adamowicz A, Kozlowski M, Wlodarczyk Z, Manitius J. Progressive arterial stiffening in kidney transplant recipients. Ann Transplant. 2011;16(3):30–5. Worsening arterial stiffness profile as time goes on in transplant patients despite.PubMed

34.

Mitchell A, Opazo Saez A, Kos M, Witzke O, Kribben A, Nurnberger J. Pulse wave velocity predicts mortality in renal transplant patients. Eur J Med Res. 2010;15(10):452–5.PubMedCrossRef

35.

Bahous SA, Stephan A, Blacher J, Safar ME. Aortic stiffness, living donors, and renal transplantation. Hypertension. 2006;47(2):216–21.PubMedCrossRef

36.

Ford ML, Tomlinson LA, Chapman TP, Rajkumar C, Holt SG. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension. 2010;55(5):1110–5.PubMedCrossRef

37.

Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens. 2010;23(3):282–9.PubMedCrossRef

38.

Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int. 2011;24(6):523–33.PubMedCrossRef

39.

Zbroch E, Malyszko J, Mysliwiec M, Przybylowski P, Durlik M. Hypertension in solid organ transplant recipients. Ann Transplant. 2012;17(1):100–7.PubMedCrossRef

40.

Wlodarczyk Z, Glyda M, Koscianska L, Kolodziejczyk J, Sulikowska B, Manitius J. Prevalence of arterial hypertension following kidney transplantation–a multifactorial analysis. Ann Transplant. 2003;8(2):43–6.PubMed

41.

Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol. 1996;7(8):1131–8.PubMed

42.

• Freedman BI, Murea M. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21–8. Relevance of genotype and target organ damage in African American patients with HTN.PubMedCrossRef

43.

Grisk O, Steinbach AC, Ciecholewski S, Schluter T, Kloting I, Schmidt H, et al. Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function. Pharmacogenet Genomics. 2009;19(4):276–88.PubMedCrossRef

44.

Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16(5):1501–11.PubMedCrossRef

45.

Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007;22(7):1963–8.PubMedCrossRef

46.

• Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11(5):1025–30. APOL1 genotype in donor puts recipient at risk for HTN and decreased allograft survival post-transplant.PubMedCrossRef

47.

• Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant. 2012;12(7):1924–8. APOL1 genotype in the recipient (not donor kidney) does not impact survival.PubMedCrossRef

48.

Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis. 1993;21(5 Suppl 2):66–72.PubMed

49.

Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346(12):913–23.PubMedCrossRef

50.

Mizuno M, Siddique K, Baum M, Smith SA. Prenatal programming of hypertension induces sympathetic overactivity in response to physical stress. Hypertension. 2013;61(1):180–6.PubMedCrossRef

51.

• Blanca L, Jimenez T, Cabello M, Sola E, Gutierrez C, Burgos D, et al. Cardiovascular risk in recipients with kidney transplants from expanded criteria donors. Transplant Proc. 2012;44(9):2579–81. Elevated cardiovascular risk in patients who receive ECD kidneys.PubMedCrossRef

52.

• Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol. 2011;7(5):659–74. Autoantibodies that activate receptors could have a role in HTN other than in preeclampsia.PubMedCrossRef

53.

Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558–69.PubMedCrossRef

54.

• Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, et al. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart. 2011;97(6):479–84. Effects of AMR on HTN and the usefulness of ARB and ACE inhibition.PubMedCrossRef

55.

Hricik DE. Antihypertensive and renal effects of enalapril in post-transplant hypertension. Clin Nephrol. 1987;27(5):250–9.PubMed

56.

• Barbari A. Posttransplant hypertension: multipathogenic disease process. Exp Clin Transplant. 2013;11(2):99–108. Focuses on various factors affecting the graft function, HTN and cardiovascular outcomes in transplantation; these factors include recipient, donor, surgical and post-transplant factors.PubMedCrossRef

57.

• Posadas MA, Yang V, Ho B, Omer M, Batlle D. Acute renal failure and severe hypertension from a Page kidney post-transplant biopsy. Sci World J. 2010;10:1539–42. Review of Page kidney, diagnosis and management including mentioning signs of acute HTN.CrossRef

58.

Akbar SA, Jafri SZ, Amendola MA, Madrazo BL, Salem R, Bis KG. Complications of renal transplantation. Radiographics. 2005;25(5):1335–56.PubMedCrossRef

59.

Molnar MZ, Szentkiralyi A, Lindner A, Czira ME, Szabo A, Mucsi I, et al. High prevalence of patients with a high risk for obstructive sleep apnoea syndrome after kidney transplantation–association with declining renal function. Nephrol Dial Transplant. 2007;22(9):2686–92.PubMedCrossRef

60.

Dolgos S, Hartmann A, Jenssen T, Isaksen GA, Pfeffer P, Bollerslev J. Determinants of short-term changes in body composition following renal transplantation. Scand J Urol Nephrol. 2009;43(1):76–83.PubMedCrossRef

61.

• Molnar MZ, Lazar AS, Lindner A, Fornadi K, Czira ME, Dunai A, et al. Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients. Clin J Am Soc Nephrol. 2010;5(1):125–32. Association of OSA and increased morbidity and mortality.PubMedCrossRef

62.

Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation. 1992;53(6):1232–5.PubMedCrossRef

63.

Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33(5):829–39.PubMedCrossRef

64.

Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet. 1996;348(9028):643–8.PubMedCrossRef

65.

Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62(11):1588–92.PubMedCrossRef

66.

Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008;19(7):1291–9.PubMedCrossRef

67.

Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307–16.PubMedCrossRef

68.

Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248(4):564–77.PubMed

69.

• Rush D. The impact of calcineurin inhibitors on graft survival. Transplant Rev (Orlando) 2013 Jun 3. The importance of CNI and their role in graft survival and preventing rejection.

70.

Campistol JM, Romero R, Paul J, Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant. 2004;19 Suppl 3:iii62–6.PubMedCrossRef

71.

Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–82.PubMedCrossRef

72.

• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010;(1):CD007893. Large database collection of the effect of cyclosporine on BP looking at trials from 1980 − 2008 showing cyclosporine significantly increases BP.

73.

Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation. 2001;72(6 Suppl):S9–S12.PubMedCrossRef

74.

Curtis JJ. Cyclosporine and posttransplant hypertension. J Am Soc Nephrol. 1992;2(12 Suppl):S243–5.PubMed

75.

Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 1985;28(5):767–74.PubMedCrossRef

76.

Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000;57(3):1100–6.PubMedCrossRef

77.

Cavarape A, Endlich K, Feletto F, Parekh N, Bartoli E, Steinhausen M. Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats. Kidney Int. 1998;53(4):963–9.PubMedCrossRef

78.

• Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol. 2012;25(3):269–75. Review of the pathophysiology of CNI-induced HTN with recent scientific findings in particular mentioning increased activity of particular channels in the renal tubules.PubMedCrossRef

79.

• Wadei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol. 2012;8(10):602–9. Review of physiology of the kidney and its role in BP control.PubMedCrossRef

80.

• Hoorn EJ, Walsh SB, McCormick JA, Furstenberg A, Yang CL, Roeschel T, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304–9. A study of the effects of CNI on the NaCl co-transporter in mice and causing HTN.PubMedCrossRef

81.

• Klein IH, Abrahams AC, van Ede T, Oey PL, Ligtenberg G, Blankestijn PJ. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens. 2010;28(9):1928–34. Sympathetic tone was increased for a short time after exposure to cyclosporine and then returned to pre-cyclosporine levels, no significant increase seen in sympathetic tone when exposed to tacrolimus.PubMedCrossRef

82.

Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS. The sodium retaining effects of cyclosporine. Kidney Int. 1992;41(6):1599–605.PubMedCrossRef

83.

Curtis JJ. Posttransplant hypertension. Transplant Proc. 1998;30(5):2009–11.PubMedCrossRef

84.

Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003;42(4):754–60.PubMedCrossRef

85.

Paul LC. Chronic allograft nephropathy: an update. Kidney Int. 1999;56(3):783–93.PubMedCrossRef

86.

Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005;5(9):2273–80.PubMedCrossRef

87.

• Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9):1587–96. Belatacept safety profile was followed over 5 years and the incidence of patients being treated for HTN was similar to the CNI group.PubMedCrossRef

88.

Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol. 2001;281(1):F38–47.PubMed

89.

Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int. 2001;59(6):2222–32.PubMed

90.

Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17(12 Suppl 3):S218–25.PubMedCrossRef

91.

• Dunn BL, Teusink AC, Taber DJ, Hemstreet BA, Uber LA, Weimert NA. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010;44(7-8):1259–70. Review from our center focused on HTN management in the transplant population.PubMedCrossRef

92.

• Fourtounas C. Management of hypertension after kidney transplantation: a possible role for spironolactone? J Hypertens. 2012;30(4):830–1. author reply 831-2. Anecdotal clinical data on use of spironolactone in the hypertensive transplant patient.PubMedCrossRef

93.

Cross NB, Webster AC, Masson P, O'connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009;88(1):7–18.PubMedCrossRef

94.

Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis. 1996;27(5):701–8.PubMedCrossRef

95.

Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):603–11.PubMedCrossRef

96.

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17(3):889–99.PubMedCrossRef

97.

• Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation. 2013;95(6):889–95. This study showed improved cardiac outcomes for renal transplant patients on ACE inhibitors over the course of 10 years.PubMedCrossRef

98.

Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol. 1995;269(4 Pt 2):F491–9.PubMed

99.

• Ibrahim HN, Jackson S, Connaire J, Matas A, Ney A, Najafian B, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24(2):320–7. Study reviewing the effects of angiotensin II blockade on transplanted kidneys in regards to fibrosis and survival.PubMedCrossRef

100.

• Townsend RR, Weir MR. Angiotensin II blockade after kidney transplantation. J Am Soc Nephrol. 2013;24(2):167–8. Editorial calling for studies involving larger groups of patients in studies looking at the transplant population, also looked at the Ibrahim et al. study on angiotensin blockade and suggested that the trends for patients on ARB was significant as GFR and fibrosis scores were more favorable in the ARB-treated group.PubMedCrossRef

101.

Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93.PubMedCrossRef

102.

• Ramesh Prasad GV. Ambulatory blood pressure monitoring in solid organ transplantation. Clin Transplant. 2012;26(2):185–91. The importance of 24 ABMP in the transplant population including screening for masked HTN, white-coat HTN and non-dipping.PubMedCrossRef

103.

Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis. 2005;45(6):994–1001.PubMedCrossRef

104.

Opelz G, Dohler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5(11):2725–31.PubMedCrossRef

105.

Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283(5):633–8.PubMedCrossRef

106.

• Wystrychowski G, Kolonko A, Chudek J, Zukowska-Szczechowska E, Wiecek A, Grzeszczak W. Systemic vascular hemodynamics and transplanted kidney survival. Transplant Proc. 2011;43(8):2922–5. Studied various vascular parameters and their relationship with IF/TA, these parameters included SBP, DBP, mean BP, pulse rate, systemic vascular resistance and impedance.PubMedCrossRef

107.

• Fernandez-Fresnedo G, Gago-Fraile M, Gomez-Alamillo C, Sanz de Castro S, Arias-Rodriguez M. Risk of cardiovascular disease associated with refractory hypertension in renal transplant recipients. Transplant Proc. 2010;42(8):2908–9. This study looked at the incidence and risk of cardiovascular disease in patients with refractory HTN.PubMedCrossRef

Titel: Hypertension after Kidney Transplantation: A Pathophysiologic Approach
verfasst von: Beje Thomas
David J. Taber
Titte R. Srinivas
Publikationsdatum: 01.10.2013
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 5/2013
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0381-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis

Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension

Determinants of Neonatal Blood Pressure

Current Insights and New Perspectives on the Roles of Hyperglucagonemia in Non-Insulin–Dependent Type 2 Diabetes

Endothelin Antagonism and Its Role in the Treatment of Hypertension